Failure by municipal and national governments in any given country to provide adequately for the needs of both small, medium and large business enterprises can significantly reduce the potential of ...
Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to ...
What AI Brings to Cybersecurity Machine-based cybersecurity has gone through several incarnations: rules-based monitoring systems, active network monitoring, and regressive analytics to remediate ...
Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...
A federal employee and contractor share their experiences in looking for new jobs since April and what others can learn from their trials and tribulations.
Researchers outline how the PhantomRaven campaign exploits hole in npm to enable software supply chain attacks.
Third quarter revenues up 6% driven by EXPAREL volume growth of 9% ---- Several key milestones advance 5x30 path to growth ...
ORLANDO, FLORIDA / ACCESS Newswire / October 31, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip ...
Iceland recorded its first verified population of mosquitoes. The cold-tolerant species Culiseta annulata survived Iceland’s ...
The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...
AllAfrica on MSN
Encouraging Results From a First-in-Human Phase 1 Clinical Trial of IAVI's Lassa Vaccine Candidate Published in New England Journal of Medicine
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways: IAVI's Lassa vaccine candidate rVSVΔG-LASV-GPC has an acceptable safety profile and ...
GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results